CALGARY, Alberta – (October 25, 2022) – Marvel Biosciences Inc. (the “Company” or “Marvel”) (TSX-V: MRVL) is pleased to announce it has completed its maximum tolerated dose (MTD) toxicology study in dogs for its product MB-204, further validating the Company’s lead drug candidate low toxicity characteristic.
“We have now completed and further validated MB-204’s safety profile through this recent dog toxicology study in addition to our recently press released toxicology study in rats,” said Dr. Mark Williams, President and Chief Science Officer of Marvel Biosciences. “We are now in the position to move to complete the 7-day dose ranging study and then our 4-week Good Laboratory Practice (GLP) toxicology study to allow us to test MB-204 in a human clinical trial,” said Dr. Mark Williams, CSO of Marvel Biosciences.
“We continue to see an aging population that suffers from complex pathologies such as Alzheimer’s Disease and depression and we are fully committed to deliver meaningful positive value to the lives of these patients,” said Rod Matheson, Chief Executive Officer of Marvel Biosciences. “So far, every study we have done continues to validate that we are on the right track with our lead candidate MB-204. We are very excited that this recent toxicology study has gotten us one step closer to beginning our human clinical trials within the first quarter of 2023.”
MTD toxicology studies define the highest dose of a drug or therapy that does not cause unacceptable side effects or toxicity. The purpose of the MTD study is to determine safe starting doses for first in-human (FIH) clinical trials. Marvel’s unique formulation increases bioavailability and absorption rate of the drug by the body. As a result, the dogs in the tests were able to successfully be exposed to the drug on a high dosage of MB-204 without adverse effects. The proven low toxicity of the MB-204 provides the Company with a great degree of confidence to enter human trials and begin the process of getting MB-204 approved by the FDA.
MB-204 is the Company’s lead compound and is a novel fluorinated form of Istradefylline (FDA approved anti-Parkinson’s disease drug) and is a blood brain barrier permeable adenosine A2a receptor antagonist. Marvel is developing MB-204 for the treatment of depression and Alzheimer’s Disease, as well NASH associated liver fibrosis.
Investor Relations: Marvel Biosciences Corp.
Virtus Advisory Group Roderick (Rod) Matheson, Chief Executive Officer or
Tel: 416-644-5081 Dr. Mark Williams, President, and Chief Science Officer
Tel: 403 770 2469
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
All information contained in this news release with respect to the Company and its subsidiary, (collectively, the “Parties”) were supplied by Marvel, respectively, for inclusion herein and each parties’ directors and officers have relied on each other for any information concerning such Party.
This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.